October 12, 2021
Back Page
41
10
How can large pharma improve D&I in its companies?
October 12, 2021
Features
41
10
Evaluating patient data in the context of complementary information can provide comprehensive market insights for product strategy.
October 12, 2021
Features
41
10
COVID may have given real-world evidence the boost it needed to become routine, especially in areas that demand research innovation and advancement.
October 12, 2021
Features
41
10
Our latest numbers crunch on biopharma financial performance—this one assessing growth and value-generation during the heart of COVID-19—reveals a mix of the familiar and new entrants into the top spots in seven business-critical metrics.
October 12, 2021
Features
41
10
Unconventional collaborations between biopharma and tech are starting to take off.
October 12, 2021
Features
41
10
While there is broad agreement that the Chief Data Officer plays a critical part in pharma, a definitive description of the role is still evolving.
October 12, 2021
Executive Profile
41
10
Imvax CEO John Furey taps into tried-and-true powers of hope and clarity as he moves the clinical stage biotech from single program to platform company.
October 12, 2021
Finance
41
10
While Q3 numbers look bleak, is improvement on the horizon?
October 12, 2021
Managed Markets
41
10
Emerging limits of one-year payer time frames.
October 12, 2021
Technology
41
10
How the sharing of scientific content with HCPs is shifting in an era of accelerated digitalization.
October 12, 2021
Leadership
41
10
Soft skills are needed to round out the hard numbers.
October 12, 2021
Global Report
41
10
New EU initiative aims to curve shortage of vaccines and therapies.
October 12, 2021
From the Editor
41
10
Examining the incumbent and imminent workforce.
October 08, 2021
Issue PDF
41
10
Click the title above for a link to open the Pharmaceutical Executive October 2021 issue in an interactive PDF format.
September 27, 2021
Washington Report
41
10
Critics say FDA is either acting too fast and risking public safety—or too slow, mired in rules while ignoring important scientific findings.